Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Pflugers Arch. 2012 Oct 7;464(6):583–592. doi: 10.1007/s00424-012-1167-y

Figure 2.

Figure 2

Blood flow analysis in the hind-limb of hypertensive (angiotensin II “Ang II” or L-NAME) and normotensive mice (sham) treated with or not treated with sodium nitrite (SN); 2A: Blood flow measured with MoorLDI-Laser in all groups (sham ± SN, Ang II ± SN and L-NAME ± SN) before and just after surgery, and once a week for 2 weeks (this image is representative of n=10); 2B: Alternative strategy for measuring Blood flow with MoorLDI-Laser in all groups (sham ± SN, Ang II ± SN and L-NAME ± SN) before and just after surgery, and once a week for 2 weeks; n=10; *P < 0.05 for sham + SN, Ang II + SN and L-NAME + SN vs. sham; $P < 0.05 statistically significant for sham + SN, Ang II + SN and L-NAME + SN vs. Ang II or L-NAME; #P<0.05 for sham + SN, L-NAME + SN, Ang II + SN vs. L-NAME or Ang II; 2C–D: Blood flow measurements in hypertensive mice treated with sodium nitrite and allopurinol (xanthine-oxido-reductase inhibitor, 100 mg/kg, i.p.) or SU-5416 (VEGF receptor antagonist, 50 mg/kg, i.p.).